Retinal Rejuvenation – naturally, from Ellex

2RT® — Retinal Rejuvenation Therapy — is Ellex’s proprietary, patented laser therapy that stimulates the eye's natural healing response to treat degenerative retinal diseases, including the early stages AMD. Ellex 2RT® features proprietary Nanopix Technology™, which teams a nanosecond laser pulse with a unique pixelated beam profile to exclusively target selected individual cells within the retinal pigment epithelium.

Stimulate the eye’s natural healing response
Stimulate the eye’s natural healing response

Positive outcomes for retinal rejuvenation

With studies demonstrating the potential for Retinal Rejuvenation Therapy to positively influence the early stages of Age-Related Macular Degeneration (AMD) and Clinically Significant Macular Edema (CSME), 2RT's non-thermal laser therapy stimulates a natural, biological healing response in the eye. 

Nanopix Technology™

Ellex 2RT® utilizes an ultra-short nanosecond laser pulse to target the compromised retinal pigment epithelium (RPE). A unique, proprietary pixelated beam profile ensures the selective targeting of nano-sized targets within the cellular structure of ageing RPE cells. With Nanopix Technology™ you can induce the orderly replacement of ageing RPE cells – without causing collateral damage to the overlying photoreceptor rods and cones of the retina.

The clinical application of Ellex’s Nanopix Technology™ is unique to Ellex 2RT® and cannot be extrapolated to other forms of retinal laser treatment, including subthreshold laser treatment.

AMD – earlier intervention

Ellex 2RT® offers the potential to intervene earlier in the disease process to improve retinal function and thereby slow the degenerative processes associated with AMD in its early stages. Clinical and scientific studies show that 2RT®  can induce a mononuclear cell response in the early intervention of AMD, including the stimulation of microglia.1,2

CSME – thermal damage avoided

Unlike conventional retinal photocoagulation, which can cause permanent damage to the eye's sensitive structures, 2RT® uses 500 times less energy than retinal photocoagulation and eliminates the incidence of heat damage to the retina and surrounding cells in the effective treatment of Clinically Significant Macular Edema (CSME).3

1. Jobling et al., “Nanosecond Laser Therapy Reverses Pathologic and Molecular Changes in Age-Related Macular Degeneration without Retinal Damage,” The FASEB Journal 29, no. 2 (February 1, 2015): 696–710, doi:10.1096/fj.14-262444.

2. Guymer, R.H., et al., Nanosecond-laser application in intermediate AMD – 12-month results of fundus appearance and macular function. Clin Experiment Ophthalmol. 2013 Oct 3. doi: 10.1111/ceo.12247.

3. Casson RJ. Et al., “Pilot randomized trial of a nanopulse retinal laser versus conventional photocoagulation for the treatment of diabetic macular oedema”, Clin Experiment Ophthalmol. 2012 Aug;40(6):604-10

2RT® employs a large 400 micron spot size, instead of the 50 micron spot size commonly used in conventional retinal laser photocoagulation.
Intuitive tablet interface allows you to select key treatment parameters.

Contact us

Ellex is the manufacturer of 2RT®. It has been approved for the indications Clinically Significant Macular Edema (CSME) and in patients with early Age-Related Macular Degeneration (AMD) where it can produce bilateral improvements in macular appearance and function under CE marking. Ellex does not accept any responsibility for use of the system outside of these indications. 

2RT®has a CE Mark (Conformité Européenne) for treatment in patients with early AMD where it can produce bilateral improvements in macular appearance and function.

2RT®has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) (510k) Market clearance for the treatment of Clinically Significant Macula Edema (CSME).

This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More